These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9455881)

  • 1. Antifungal activity of a human antiglucuronoxylomannan antibody.
    Zhong Z; Pirofski LA
    Clin Diagn Lab Immunol; 1998 Jan; 5(1):58-64. PubMed ID: 9455881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
    Zhang H; Zhong Z; Pirofski LA
    Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
    Netski D; Kozel TR
    Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.
    Mukherjee S; Lee SC; Casadevall A
    Infect Immun; 1995 Feb; 63(2):573-9. PubMed ID: 7822024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody.
    Lee SC; Kress Y; Dickson DW; Casadevall A
    J Neuroimmunol; 1995 Oct; 62(1):43-52. PubMed ID: 7499491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies.
    Zhong Z; Pirofski LA
    Infect Immun; 1996 Sep; 64(9):3446-50. PubMed ID: 8751883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
    Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.
    Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G
    Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
    Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
    J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.
    Houpt DC; Pfrommer GS; Young BJ; Larson TA; Kozel TR
    Infect Immun; 1994 Jul; 62(7):2857-64. PubMed ID: 8005676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
    Todaro-Luck F; White EH; Reiss E; Cherniak R
    Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
    Duro RM; Netski D; Thorkildson P; Kozel TR
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
    Martinez LR; Moussai D; Casadevall A
    Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
    Casadevall A; Cleare W; Feldmesser M; Glatman-Freedman A; Goldman DL; Kozel TR; Lendvai N; Mukherjee J; Pirofski LA; Rivera J; Rosas AL; Scharff MD; Valadon P; Westin K; Zhong Z
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1437-46. PubMed ID: 9624491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
    Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
    Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-mediated recognition of Cryptococcus neoformans.
    Levitz SM
    Nihon Ishinkin Gakkai Zasshi; 2002; 43(3):133-6. PubMed ID: 12145626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans.
    Rakesh V; Schweitzer AD; Zaragoza O; Bryan R; Wong K; Datta A; Casadevall A; Dadachova E
    J Phys Chem B; 2008 Jul; 112(29):8514-22. PubMed ID: 18588334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
    Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
    Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.